egfr-mutated nsclc; where we are now?
Published 5 years ago • 336 plays • Length 5:28Download video MP4
Download video MP3
Similar videos
-
4:51
understanding egfr-mutant nsclc subsets
-
9:30
egfr testing for nsclc
-
5:55
surgery options for nsclc & i-o therapy in egfr-mutations
-
7:08
emerging data in egfr-mutant lung cancer
-
58:24
time for even more precision in testing and treatment of egfr-mutated nsclc
-
6:56
first-line therapy in the patient with egfr-mutant lung cancer
-
1:05:12
new horizons in egfr-mutated nsclc: broadening the impact of precision testing
-
5:52
treatment of egfr nsclc after osimertinib
-
5:02
egfr-mutant lung cancer: initial approach
-
6:06
osimertinib, the standard for egfr nsclc
-
1:37
dr. konduri on treatment options for patients with egfr-mutant nsclc
-
6:57
egfr exon 20 mutations in non–small cell lung cancer
-
1:02:40
new milestones and changing standards of care in early egfr-mutated nsclc
-
3:41
how do doctors treat lung cancer with egfr mutations?
-
6:22
osimertinib’s role in egfr metastatic lung cancer
-
7:00
researcher comment: dual egfr inhibition for egfr-mutated nsclc | julia rotow
-
13:06
managing t790-negative egfr-mutated nsclc
-
3:15
does the specific egfr mutation matter when choosing an oral egfr inhibitor?
-
3:24
sequencing of therapies in egfr-mutant nsclc